Terms: = Endocrine gland cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
55 results:
1. Machine learning developed a PI3K/akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract] [Full Text] [Related]
2. The Role of Activation of PI3K/akt/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/akt activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract] [Full Text] [Related]
4. outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review.
Raymond P; Raverot G; Ilie MD
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36852675
[TBL] [Abstract] [Full Text] [Related]
5. Pancancer analysis of SKA1 mutation and its association with the diagnosis and prognosis of human cancers.
Lan H; Yuan J; Zhang R; Jiang B; Li Q; Huang Z; Chen P; Xiang H; Zeng X; Xiao S
Genomics; 2023 Mar; 115(2):110554. PubMed ID: 36587749
[TBL] [Abstract] [Full Text] [Related]
6. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
7. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy.
Feng H; Qiu L; Shi Z; Sheng Y; Zhao P; Zhou D; Li F; Yu H; You Y; Wang H; Li M; Zhu S; Du Y; Cui J; Sun J; Liu Y; Jiang H; Wu X
Cancer Med; 2023 Feb; 12(3):3313-3327. PubMed ID: 36028997
[TBL] [Abstract] [Full Text] [Related]
8. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract] [Full Text] [Related]
10. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Nicolle R; Blum Y; Duconseil P; Vanbrugghe C; Brandone N; Poizat F; Roques J; Bigonnet M; Gayet O; Rubis M; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Giovannini M; Grandval P; Garcia S; Canivet C; Cros J; Bournet B; Buscail L; ; Moutardier V; Gilabert M; Iovanna J; Dusetti N
EBioMedicine; 2020 Jul; 57():102858. PubMed ID: 32629389
[TBL] [Abstract] [Full Text] [Related]
11. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/akt/NF-κB/IL-8 signalling in ovarian cancer.
Jiang YX; Siu MK; Wang JJ; Mo XT; Leung TH; Chan DW; Cheung AN; Ngan HY; Chan KK
Br J Cancer; 2020 Jul; 123(2):275-287. PubMed ID: 32390009
[TBL] [Abstract] [Full Text] [Related]
12. Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic cancer.
Nair N; Chen SY; Lemmens E; Chang S; Le DT; Jaffee EM; Murphy A; Whiting C; Müller T; Brockstedt DG
Cancer Immunol Res; 2020 May; 8(5):609-617. PubMed ID: 32132105
[TBL] [Abstract] [Full Text] [Related]
13. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
14. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities.
Liu G; Ruan G; Huang M; Chen L; Sun P
Aging (Albany NY); 2020 Jan; 12(1):178-192. PubMed ID: 31895688
[TBL] [Abstract] [Full Text] [Related]
15. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.
Wang ZX; Deng TX; Ma Z
J Cell Biochem; 2019 Oct; 120(10):16416-16426. PubMed ID: 31297864
[TBL] [Abstract] [Full Text] [Related]
17. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian cancers.
Bischof K; Knappskog S; Hjelle SM; Stefansson I; Woie K; Salvesen HB; Gjertsen BT; Bjorge L
Sci Rep; 2019 Mar; 9(1):5244. PubMed ID: 30918304
[TBL] [Abstract] [Full Text] [Related]
18. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
[TBL] [Abstract] [Full Text] [Related]
19. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
20. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract] [Full Text] [Related]
[Next]
